022 Meds Management: Drugs monitoring suite
The Drugs Monitoring Suite folder forms part of 022 Meds Management
The Drugs Monitoring Suite searches are designed to identify patients on various medication who require monitoring, and whether that monitoring is due.
Features include:
- Empowers staff to check for single drugs’ monitoring, or drugs across all patients
- Instantly see which patients are due monitoring for a range of tests including LFTs, eGFRs, BPs and more
- Patients who are due for monitoring on two or more drugs are identified in a distinct report to enable focused recall
- A separate folder for drugs with undefined monitoring requirements is included
Like all PCIT searches, clinical judgement must be taken when using these. The timeframes follow suggestions from NICE-CKS and SPS, but each drug will have patients that require more frequent monitoring as appropriate.
What follows is a description of each folder and an explanation of its content.
PCIT do not recommend running the Drugs monitoring suite top-level folder. Instead, run one of the lower folders e.g. Actions.
These folders can be run either using today's date or a relative run date to assess Practice monitoring compliance over time.
Actions
Due monitoring single drug - every patient who appears in this report appears on only one of the drug groups. See below (Single Drug Monitoring Overdue) for the full list of drugs that are included.
Due monitoring two or more drugs - every patient who appears in this search appears on two or more drug groups. This list has been split out separately in case the required monitoring of two or more drugs overlaps - in this way, there is less chance of having to recall the patient multiple times.
These two reports are non-specific and will show the latest results for every test - this does not mean each patient needs every test.
Potential Monitoring
Drug (report name) | Monitoring |
Flutamide (established) | LFT every 12 months |
Naltrexone | LFT every 12 months |
Pioglitazone | LFT every 12 months |
Piracetam | If latest eGFR less than 60, carry out a CrCl |
Propylthiouracil | LFT every 12 months |
Rilizole (established) | LFT every 12 months |
These drugs have poorly-defined monitoring requirements, typically "as clinically indicated". We have put a 12 month check on whichever monitoring is required.
Single Drug Monitoring Overdue
Use these reports to monitor individual drugs. Note that patients who appear in two or more drugs will instead appear in the Due monitoring two or more drugs
The following time periods are used to flag patients:
Time period of required monitoring: | Patient will be flagged from: |
Every 12 months | 10 months |
Every 6 months | 22 weeks |
Every 3 months | 10 weeks |
Every 1 month | 3 weeks |
Where a drug is "established", this means the patient has been on it for more than 12 months
Drug (report name) | Monitoring | Timeframe justification |
ACEi ARB (with Heart Failure) | U&Es every 6 months | "Measure renal function and electrolyte levels every 3 to 6 months once the maximum tolerated dose has been established" - NICE CKS "Ongoing once stable - 6 monthly" - SPS |
ACEi ARB | U&Es every 12 months | "Hypertension or Post myocardial infarction - Ongoing once stable - annually" - SPS |
Acetazolamide | FBC and U&Es every 12 months | |
Alfacalcidol | U&Es every 1 months and LFT every 12 months | |
Amiodarone | U&Es and LFTs every 6 months | |
Amisulpiride | FBC and U&Es and LFT every 12 months | |
Atomoxetine | BP and BMI and Pulse every 6 months | |
Azathioprine | FBC and U&Es and LFT every 3 months | |
Balsalazide | U&Es every 12 months | |
Carbamazepine | FBC and LFT every 12 months, U&Es every 6 months | |
Ciclosporin levels | This report will show every patient's latest ciclosporin level | |
Ciclosporin (systemic) | FBC and U&Es and LFT every 1 month | |
Cinacalcet | Calcium every 3 months | |
Clonidine | BP and BMI and Pulse every 6 months | |
Cyproterone | FBC every 12 months and LFT every 3 months | |
Dapsone | FBC every 3 months | |
Dexamfetamine | BP and BMI and Pulse every 6 months | |
Digoxin | U&Es every 12 months | |
Disulfiram | LFT every 6 months | |
Diuretics | U&Es every 12 months | |
Dronedarone (established) | U&Es and LFT every 12 months | |
Dronedarone (Unestablished) | U&Es every 12 months and LFT every 3 months | |
Flutamide (Unestablished) | LFT every 1 month | |
Guanfacine | BP and BMI and Pulse every 6 months | |
Hydroxycarbamide | FBC and U&Es and LFT every 3 months | |
Hydroxychloroquine | U&Es and LFT every 12 months | |
Ibandronic acid | U&Es, Bone profile, phosphate and magnesium every 12 months | |
Ketoconazole | LFT every 3 months | |
Leflunomide (no methotrexate) | FBC and U&Es and LFT every 3 months | |
Lisdexamfetamine | BP and BMI and Pulse every 6 months | |
Lithium | U&Es, TSH and calcium every 6 months, lithium every 4 months | |
Mercaptopurine | FBC and U&Es and LFT every 3 months | |
Mesalazine | FBC and U&Es and LFT every 6 months | |
Metformin | U&Es every 12 months | |
Methotrexate (no leflunomide) | FBC and U&Es and LFT every 3 months | |
Methotrexate (with leflunomide) | FBC and U&Es and LFT every 1 months | |
Methylphenidate | BP and BMI and Pulse every 6 months | |
Minocycline | LFT every 3 months | |
Mirabegron | BP every 6 months | |
Mycophenolate | FBC and U&Es and LFT every 3 months | |
Nitrofurantoin | LFT every 12 months | |
NSAID | FBC and U&Es every 12 months | |
Olanzapine | FBC and U&Es and LFT every 12 months | |
Penicillamine | FBC and U&Es and LFT every 3 months | |
Phenytoin | FBC and LFT every 12 months | |
Quetiapine | FBC and U&Es and LFT every 12 months | |
Rilizole (Unestablished) | LFT every 3 months | |
Risperidone | FBC and U&Es and LFT every 12 months | |
Sirolimus | FBC and U&Es and LFT every 12 months | |
Sodium valproate monitoring | FBC and U&Es and LFT every 12 months | |
Spironolactone (HF or ACEi/ARB) | U&Es every 3 months | |
Spironolactone (not HF or ACEi/ARB) | U&Es every 12 months | |
Sulfasalazine (Established) | U&Es every 12 months | |
Sulfasalazine (Unestablished) | FBC and U&Es and LFT every 3 months | |
Tacrolimus | FBC and U&Es and LFT every 12 months | |
Testosterone | FBC every 12 months and PSA monitoring if male and 45 or over | |
Theophylline | U&Es every 12 months | |
Tolcapone | LFT every 2 months |
Initial release April 2025
Related Articles
022 Meds Management Overview
Overview The EMIS search folder 022 Meds Management brings together groups of searches and reports under the umbrella of medicines monitoring. This set of searches cover an expanding range of topics. Additional support articles linked below will help ...022 Meds Management: OneDrug Risk
The OneDrugRisk searches are designed to identify patients who have: Monitoring requirements outstanding Hazard scenarios present Quality issues identified The OneDrugrisk folder forms part of 022 Meds Management In order to understand the ...022 Meds Management: HRT
The Hormone Replacement Therapy searches are designed to identify patients on HRT medication who require annual monitoring. The HRT folder forms part of 022 Meds Management Patients on HRT should be monitored at least annually. The report pulls out ...022 Meds Management: Bisphosphonate
The Bisphosphonate prescribing searches are designed to identify patients who are currently prescribed a bisphosphonate medication on repeat, and have had an issue in the last 3 months. The Bisphosphonate folder forms part of 022 Meds Management ...022 Meds Management: Insomnia
The Insomnia searches are designed to identify patients who have been prescribed a Z drug (Zopiclone or Zolpidem) in the last 3 months to help monitor prescribing safely. The Insomnia folder forms part of 022 Meds Management The search contains ...